PL2605764T3 - Kompozycje do leczenia nowotworu - Google Patents

Kompozycje do leczenia nowotworu

Info

Publication number
PL2605764T3
PL2605764T3 PL11749393T PL11749393T PL2605764T3 PL 2605764 T3 PL2605764 T3 PL 2605764T3 PL 11749393 T PL11749393 T PL 11749393T PL 11749393 T PL11749393 T PL 11749393T PL 2605764 T3 PL2605764 T3 PL 2605764T3
Authority
PL
Poland
Prior art keywords
cancer
compositions
treatment
Prior art date
Application number
PL11749393T
Other languages
English (en)
Inventor
Kapil Dhingra
Brian Higgins
Kenneth Kolinsky
Richard J Lee
Brian Lestini
Kathryn E Packman
Fei Su
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44532840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2605764(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PL2605764T3 publication Critical patent/PL2605764T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL11749393T 2010-08-17 2011-08-16 Kompozycje do leczenia nowotworu PL2605764T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37429610P 2010-08-17 2010-08-17
EP11749393.2A EP2605764B1 (en) 2010-08-17 2011-08-16 Compositions for the treatment of cancer
PCT/EP2011/064050 WO2012022724A1 (en) 2010-08-17 2011-08-16 Combination anti - cancer therapy

Publications (1)

Publication Number Publication Date
PL2605764T3 true PL2605764T3 (pl) 2015-08-31

Family

ID=44532840

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11749393T PL2605764T3 (pl) 2010-08-17 2011-08-16 Kompozycje do leczenia nowotworu

Country Status (26)

Country Link
US (1) US8709419B2 (pl)
EP (1) EP2605764B1 (pl)
JP (1) JP5758003B2 (pl)
KR (1) KR101475167B1 (pl)
CN (1) CN103153292B (pl)
AR (1) AR082691A1 (pl)
AU (1) AU2011290818B2 (pl)
BR (1) BR112013003530A2 (pl)
CA (1) CA2807222A1 (pl)
DK (1) DK2605764T3 (pl)
ES (1) ES2535000T3 (pl)
HR (1) HRP20150648T1 (pl)
HU (1) HUE025187T2 (pl)
IL (1) IL224395A (pl)
MX (1) MX349878B (pl)
MY (1) MY161288A (pl)
NZ (1) NZ606251A (pl)
PL (1) PL2605764T3 (pl)
PT (1) PT2605764E (pl)
RS (1) RS53959B1 (pl)
RU (1) RU2607596C2 (pl)
SG (1) SG188207A1 (pl)
SI (1) SI2605764T1 (pl)
TW (1) TWI530287B (pl)
WO (1) WO2012022724A1 (pl)
ZA (1) ZA201300967B (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3129329B2 (ja) 1991-02-26 2001-01-29 東芝ライテック株式会社 照明器具
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
PL2672967T3 (pl) * 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
SI2884979T1 (sl) 2012-08-17 2019-10-30 Hoffmann La Roche Kombinirana zdravljenja melanoma, ki vključujejo dajanje kobimetiniba in vemurafeniba
RU2016134406A (ru) 2014-01-24 2018-03-01 Лэм Терапьютикс, Инк. Композиции апилимода и способы их применения
WO2015156674A2 (en) * 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
PL3215158T3 (pl) 2014-11-07 2019-11-29 Ai Therapeutics Inc Apilimod do zastosowania do leczenia raka nerki
MX393780B (es) 2017-01-17 2025-03-24 Heparegenix Gmbh Inhibidores de proteina cinasa para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocitos
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) * 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516807A (en) * 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
ATE330600T1 (de) 2000-01-26 2006-07-15 Schering Corp Kombinationspräparat zur krebstherapie
US6545010B2 (en) 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
CA2408710C (en) 2000-05-15 2010-01-26 Celgene Corp. Compositions and methods for the treatment of colorectal cancer
BR0114598A (pt) 2000-10-13 2003-07-01 Vion Pharmaceuticals Inc Pró-droga modificada das formas ap/amp
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
CA2383259A1 (en) 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
US20080193445A1 (en) 2002-01-18 2008-08-14 Liliane Goetsch Novel anti-IGF-IR antibodies and uses thereof
US20050176740A1 (en) * 2002-04-08 2005-08-11 Spector Neil L. Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US20070281041A1 (en) 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
TW200533339A (en) 2004-03-16 2005-10-16 Bristol Myers Squibb Co Therapeutic synergy of anti-cancer compounds
KR100851271B1 (ko) * 2004-06-03 2008-08-08 에프. 호프만-라 로슈 아게 이리노테칸 （ｃｐｔ-１１） 및 ｅｇｆｒ-억제제를 이용한치료
NZ551355A (en) 2004-06-03 2009-09-25 Hoffmann La Roche Treatment of cancer with irinotecan (CPT-11) and erlotinib
KR20080003422A (ko) 2005-04-14 2008-01-07 메르크 파텐트 게엠베하 종양 조직 내의 ｅｇｆｒ 유전자의 증가된 복제수에 기초한항-ｅｇｆｒ 항체 치료
EP1917019A2 (en) 2005-05-03 2008-05-07 Biopolymer Engineering, Inc. Combination of a beta-glucan and an egf receptor antagonist for the treatment of cancer and infection
US20060257400A1 (en) 2005-05-13 2006-11-16 Bristol-Myers Squibb Company Combination therapy
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
EP2311814A1 (en) 2005-12-01 2011-04-20 F. Hoffmann-La Roche AG 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
CN101541977A (zh) 2006-09-19 2009-09-23 诺瓦提斯公司 用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
PE20081581A1 (es) * 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
US20100104567A1 (en) 2007-03-05 2010-04-29 Kyowa Hakko Kirin Co., Ltd. Pharmaceutical composition
JP5563455B2 (ja) 2007-08-01 2014-07-30 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の新規な合成アゴニスト
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
AU2010236606A1 (en) 2009-04-14 2011-11-03 Merck Sharp & Dohme Corp. Interferon-alfa sensitivity biomarkers
JP5469744B2 (ja) 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
JP2013502236A (ja) 2009-08-24 2013-01-24 ジェネンテック， インコーポレイテッド Ｋｒａｓ変異及びｒｔｋ発現レベルを検出することによるｂ−ｒａｆ阻害剤治療に対する細胞の感受性の決定
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders

Also Published As

Publication number Publication date
MX349878B (es) 2017-08-16
HUE025187T2 (en) 2016-07-28
IL224395A (en) 2017-09-28
KR101475167B1 (ko) 2014-12-19
NZ606251A (en) 2015-02-27
BR112013003530A2 (pt) 2016-06-28
AU2011290818A1 (en) 2013-02-07
KR20130043225A (ko) 2013-04-29
TWI530287B (zh) 2016-04-21
EP2605764B1 (en) 2015-03-18
AR082691A1 (es) 2012-12-26
DK2605764T3 (en) 2015-04-07
AU2011290818B2 (en) 2015-08-27
ES2535000T3 (es) 2015-05-04
HRP20150648T1 (hr) 2015-07-31
US20120045434A1 (en) 2012-02-23
SI2605764T1 (sl) 2015-06-30
SG188207A1 (en) 2013-04-30
MX2013001518A (es) 2013-02-27
RU2013110124A (ru) 2014-09-27
CA2807222A1 (en) 2012-02-23
MY161288A (en) 2017-04-14
EP2605764A1 (en) 2013-06-26
JP2013537544A (ja) 2013-10-03
PT2605764E (pt) 2015-06-02
CN103153292B (zh) 2016-06-29
JP5758003B2 (ja) 2015-08-05
RU2607596C2 (ru) 2017-01-10
CN103153292A (zh) 2013-06-12
ZA201300967B (en) 2015-11-25
US8709419B2 (en) 2014-04-29
WO2012022724A1 (en) 2012-02-23
RS53959B1 (sr) 2015-08-31
TW201212915A (en) 2012-04-01

Similar Documents

Publication Publication Date Title
IL251083A0 (en) Compounds and preparations for the treatment of cancer
IL225471B (en) Preparations for the prevention and treatment of cancer
SG10201508495VA (en) Combination treatment of cancer
SI2605764T1 (sl) Sestavki za zdravljenje raka
IL232530A0 (en) Combined cancer treatment
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL215772A0 (en) Composition for the treatment of prostate cancer
IL222958A0 (en) Cancer treatment
IL214349A0 (en) Compositions and methods for the treatment of cancer
ZA201300762B (en) Novel combination therapy for the treatment of cancer
SMT201900749T1 (it) Composizione per il trattamento dell'infertilita'
PL2460509T3 (pl) Kompozycja do leczenia brodawek
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
GB201017356D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201301168D0 (en) Cancer treatment
HU1000559D0 (en) Pharmaceutical compositions for the treatment of osteoporosis and cancer
GB201012310D0 (en) Composition for the treatment of botulism
GB201002499D0 (en) Treatment of tumours
AU2010904107A0 (en) Treatment of cancer
IL223055A0 (en) Compositions for the treatment of gynaecological disorders
HK1195925A (en) Methods and compositions for the treatment and diagnosis of cancer
GB201019034D0 (en) Treatment for tumors